

AVITA MEDICAL, INC.

ARBN 641 288 155

Results for announcement to the market

Financial Results (in thousands)				June 2025	June 2024
Total revenue	Up	18%	to	\$ 36,932	\$ 26,299
Other income	Up	42%	to	1,693	1,544
Net loss	Down	30%	to	23,779	34,051
Total other comprehensive loss for the period	Down	29%	to	23,919	34,321

Dividends	Amount per ordinary security	Franked amount per security
2025 interim dividend	Nil	Nil
2024 interim dividend	Nil	Nil

Record date for determining entitlements to the 2024 interim dividends	N/A
--	-----

Net Tangible Asset Backing	June 2025	June 2024
Net tangible asset backing per ordinary security	\$ (0.7999)	\$ 0.7641

Other explanatory notes		
	June 2025	June 2024
<i>Net Tangible Assets:</i>		
Net assets	\$ (12,847,338)	\$ 24,310,593
Right of use assets	(3,132,197)	(3,937,774)
Intangibles	(5,308,140)	(545,472)
Total net tangible assets	<u>\$ (21,287,674)</u>	<u>\$ 19,827,348</u>
<i>Number of ordinary shares on issue</i>	26,613,678	25,949,906
Net tangible asset backing per ordinary security	<u>\$ (0.7999)</u>	<u>\$ 0.7641</u>

Additional information

Continued investment in research and development, notably an increase in intangible assets

Operating losses during the 1H of 2025 reflecting the Company's growth-stage as commercial activities scale up

An increase in working capital liabilities in support of growth

Reduction in net loss as the Company focuses on profitability and cash flow break even in 2026

Additional disclosure and further commentary on these results is contained in the attached Form 10-Q for the three months and six months ended June 30, 2025.

For personal use only